HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Notes PPI Dermatosis Risk: Will FDA Make Similar Communication?

This article was originally published in The Tan Sheet

Executive Summary

The UK drug regulator announces “a very low risk” of sub-acute cutaneous lupus erythematosus from use of PPIs, which are available there with the same ingredients approved for use in the US in products available OTC and RX – esomeprazole, lansoprazole and omeprazole – and Rx only, pantoprazole and rabeprazole.

You may also be interested in...

UK Nexium Ad Rapped For Downplaying Treatment For Persistent Heartburn

Pfizer’s TV ad for Nexium Control short-term heartburn treatment implied consumers with persistent heartburn need not seek professional medical advice, UK Advertising Standards Authority says. Pfizer argued that information in the ad was in line with MHRA's approval for the drug’s indications and packaging warned consumers not to use more than 14 days.

Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings

CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.

Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels

Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts